Nicoleta, our Health Resource Consultant, asked her pharmacist if tariffs could impact drug availability for people with EDS. The answer? No one knows for sure.
But a recent @globeandmail article is a major wake-up call. It follows one anti-anxiety pill’s 52,000 km journey across China, India, Germany, the U.S., and Canada, revealing just how fragile and global drug supply chains really are. 🌍💊
📌 Even one small disruption — like a tariff — could mean delays or shortages for critical medications many with EDS, HSD, or comorbidities depend on.
📰 Read the article:
How one anti-anxiety pill’s 52,000 km journey to Canada highlights Big Pharma’s complex supply chains
👥 Talk to your pharmacist about potential risks and stay informed. Our health depends on it.
#EDS #ChronicIllness #DrugShortages #Tariffs #GlobalHealth #HealthcareAccess #SupplyChain #MedicationsMatter
